The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates ...

Humira is the company's blockbuster immunology ... It raised its combined outlook for psoriasis treatment Skyrizi and arthritis drug Rinvoq to more than $31 billion through 2027 and said it ...

Q. Is there any cure for psoriasis? A. There’s no cure for psoriasis yet, but there are many ways to get relief from the symptoms of this troublesome disease. Psoriasis is one of the most ...

with the latter two rivalling Humira in indications such as rheumatoid arthritis and psoriasis. Kavya Gopal, head of specialty at Sandoz UK, said: “Biosimilars offer the NHS the potential to ...